BioCentury | Jun 8, 2015
Company News

Urigen, Imprimis deal

...Imprimis exercised its option to convert its non-exclusive, U.S. license to Urigen’s Hep-Lido-A to an exclusive...
...formulation of heparin and alkalinized lidocaine is marketed to treat interstitial cystitis/bladder pain syndrome (IC/BPS). Urigen...
...dose or 15-20% of Imprimis’ net sales. Imprimis received the non-exclusive right in October 2014. Urigen Pharmaceuticals Inc....
BioCentury | May 11, 2015
Financial News

Urigen withdraws IPO

...Urigen Pharmaceuticals Inc. , North Brunswick, N.J. Business: Genitourinary Date announced: 2015-05-04 Type: IPO Note: Urigen...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...Valeritas Inc. 2/12/15 $75M Mkt (device) Klox Technologies Inc. 2/11/15 Up to $75M Development (device) Urigen Pharmaceuticals Inc....
BioCentury | Feb 16, 2015
Financial News

Urigen proposes IPO

...2015-02-11 Type: IPO To be raised: Up to $25 million Shares: TBD Price: TBD Note: Urigen...
BioCentury | Apr 15, 2013
Financial News

Urigen financial update

...Urigen announced that the SEC decided to revoke the company's registered securities. Urigen has been delinquent...
...in its SEC filings since failing to timely file its Form 10-K in September 2010. Urigen...
...appeal the decision, which is expected to become final on or around Oct. 10. *** Urigen Pharmaceuticals Inc....
BioCentury | Oct 24, 2011
Financial News

Urigen completes private placement of convertible notes and warrants

Urigen Pharmaceuticals Inc. (Pink:URGP), Walnut Creek, Calif. Business: Genitourinary Date completed: 10/14/11 Type: Private placement of convertible notes and warrants Raised: $300,000 Shares outstanding prior: 86.2 million Note: The two-year notes bear a 10% coupon...
BioCentury | Jul 11, 2011
Company News

Urigen management update

Urigen Pharmaceuticals Inc. (Pink:URGP), Walnut Creek, Calf. Business: Genitourinary Resigned: Martin Shmagin as CFO and a director Transitioned: Dan Vickery to chairman and secretary from a director WIR Staff Genitourinary...
BioCentury | Jul 12, 2010
Company News

Urigen management update

Urigen Pharmaceuticals Inc. (OTCBB:URGP), San Francisco, Calif. Business: Genitourinary Hired: Lowell Parsons, a director, as CMO WIR Staff Genitourinary...
BioCentury | May 10, 2010
Financial News

Urigen financial update

...at $0.10. The investor also receives five-year warrants to purchase 5.5 million shares a $0.13. Urigen Pharmaceuticals Inc....
BioCentury | May 3, 2010
Company News

Oceana, Urigen deal

...2009 deal that gave Oceana a right of first refusal to license all indications of Urigen's...
...be approved by FDA. Under the terms of the original agreement, Oceana was to assist Urigen...
...and pay up to $50,000 in fees to Urigen's consultants in connection with the meeting. Urigen...
Items per page:
1 - 10 of 39
BioCentury | Jun 8, 2015
Company News

Urigen, Imprimis deal

...Imprimis exercised its option to convert its non-exclusive, U.S. license to Urigen’s Hep-Lido-A to an exclusive...
...formulation of heparin and alkalinized lidocaine is marketed to treat interstitial cystitis/bladder pain syndrome (IC/BPS). Urigen...
...dose or 15-20% of Imprimis’ net sales. Imprimis received the non-exclusive right in October 2014. Urigen Pharmaceuticals Inc....
BioCentury | May 11, 2015
Financial News

Urigen withdraws IPO

...Urigen Pharmaceuticals Inc. , North Brunswick, N.J. Business: Genitourinary Date announced: 2015-05-04 Type: IPO Note: Urigen...
BioCentury | Apr 6, 2015
Finance

Fundamental rally

...Valeritas Inc. 2/12/15 $75M Mkt (device) Klox Technologies Inc. 2/11/15 Up to $75M Development (device) Urigen Pharmaceuticals Inc....
BioCentury | Feb 16, 2015
Financial News

Urigen proposes IPO

...2015-02-11 Type: IPO To be raised: Up to $25 million Shares: TBD Price: TBD Note: Urigen...
BioCentury | Apr 15, 2013
Financial News

Urigen financial update

...Urigen announced that the SEC decided to revoke the company's registered securities. Urigen has been delinquent...
...in its SEC filings since failing to timely file its Form 10-K in September 2010. Urigen...
...appeal the decision, which is expected to become final on or around Oct. 10. *** Urigen Pharmaceuticals Inc....
BioCentury | Oct 24, 2011
Financial News

Urigen completes private placement of convertible notes and warrants

Urigen Pharmaceuticals Inc. (Pink:URGP), Walnut Creek, Calif. Business: Genitourinary Date completed: 10/14/11 Type: Private placement of convertible notes and warrants Raised: $300,000 Shares outstanding prior: 86.2 million Note: The two-year notes bear a 10% coupon...
BioCentury | Jul 11, 2011
Company News

Urigen management update

Urigen Pharmaceuticals Inc. (Pink:URGP), Walnut Creek, Calf. Business: Genitourinary Resigned: Martin Shmagin as CFO and a director Transitioned: Dan Vickery to chairman and secretary from a director WIR Staff Genitourinary...
BioCentury | Jul 12, 2010
Company News

Urigen management update

Urigen Pharmaceuticals Inc. (OTCBB:URGP), San Francisco, Calif. Business: Genitourinary Hired: Lowell Parsons, a director, as CMO WIR Staff Genitourinary...
BioCentury | May 10, 2010
Financial News

Urigen financial update

...at $0.10. The investor also receives five-year warrants to purchase 5.5 million shares a $0.13. Urigen Pharmaceuticals Inc....
BioCentury | May 3, 2010
Company News

Oceana, Urigen deal

...2009 deal that gave Oceana a right of first refusal to license all indications of Urigen's...
...be approved by FDA. Under the terms of the original agreement, Oceana was to assist Urigen...
...and pay up to $50,000 in fees to Urigen's consultants in connection with the meeting. Urigen...
Items per page:
1 - 10 of 39